



Bruce Kinon, MD
Independent

Bruce J. Kinon, M.D. is a clinical research psychiatrist with an extensive history of clinical drug development. Most recently, Dr Kinon has served as the Vice President, Clinical Research and Development, Psychiatry, at Lundbeck Pharmaceuticals LLC, the US affiliate of the global pharmaceutical company H. Lundbeck A/S headquartered in Denmark. Lundbeck is engaged in the research and development, production, marketing, and sale of drugs for the treatment of disorders in the central nervous system and is committed to improve the quality of life of people suffering from psychiatric and neurological disorders. Dr. Kinon's responsibilities included the development of innovative drug treatments for neuropsychiatric disorders with significant unmet medical needs and the effective delivery into clinical practice of new pharmacologic therapies for the psychoses and affective disorders.

Dr. Kinon received his M.D. training at the New York University (NYU) School of Medicine and completed his residency in psychiatry at the NYU-Bellevue Hospital Medical Center in New York City. He has had a long and productive career in the field of neuropsychopharmacology spanning many years in academic research and practice at the Long Island Jewish-Hillside Medical Center in New York, a NIMH center of schizophrenia research, and in the pharmaceutical industry. At Eli Lilly and Company, Dr. Kinon led, in part, the development and commercialization of the eminently successful atypical antipsychotic drug Zyprexa and, later, the development of novel glutamate-based schizophrenia therapies, including the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil. At Lundbeck, he has led multi-functional teams investigating potential and novel therapies for the disabling negative symptoms associated with schizophrenia and for treatment resistant schizophrenia. Dr. Kinon has recently been investigating innovative synaptic and circuit-based central nervous system targets with possible transdiagnostic treatment effects.

Dr. Kinon is an internationally recognized expert who has contributed significantly to the development of first-in-class treatments for unmet needs in serious mental disorders, safety and efficacy clinical research trials, outcomes research for real-world evidence of psychiatric morbidity, global marketing strategies consistent with the patient journey and health transaction models, and to the comprehensive foundational knowledge of the schizophrenia and depression disease states. He has published extensively in internationally recognized peer-reviewed journals and is a frequently invited chair or participant in

panels at international psychiatric and psychopharmacology scientific congresses. He presently serves as a consultant to the pharmaceutical industry.